BioSpace News Archive

Vivos Therapeutics, Inc. today announced that it plans to release financial results for the second quarter ended June 30, 2022 after market close on Monday, August 15, 2022.

Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today reported financial results for the quarter ended June 30, 2022 and provided a company update.

Agenus Inc., an immuno-oncology company with an extensive pipeline of therapeutics designed to activate the immune response to cancers and infections, provided a corporate update and reported financial results for the second quarter of 2022.

Prelude Therapeutics Incorporated today reported financial results for the second quarter ended June 30, 2022 and provided an update on recent clinical and development pipeline progress.

Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today announced the publication of preclinical study results demonstrating the successful generation, durable anti-tumor response, and functional persistence of TCR-CAR+ iPSC-derived CD8αβ T cells from induced pluripotent stem cells (iPSCs).

Blue Water Vaccines Inc. today announced that it has entered into definitive agreements with several healthcare-focused institutional investors for the purchase of 3,683,280 shares of common stock (or common stock equivalents in lieu thereof) in a private placement priced at-the-market under Nasdaq rules.

Formosa Pharmaceuticals, Inc. and AimMax Therapeutics, Inc. report successful top-line results from CPN-302, the second of the two pivotal Phase 3 clinical studies of APP13007, a novel ophthalmic nanosuspension formulation of the potent corticosteroid, clobetasol propionate (0.05%), for the treatment of inflammation and pain after cataract surgery.

Veritiv Corporation (NYSE: VRTV), a full-service provider of business-to-business products, services and solutions, today announced financial results for the second quarter ended June 30, 2022.

IceCure Medical Ltd. today announced it will report its business and financial results as of and for the six months ended June 30, 2022 on Monday, August 15, 2022 with a press release issued at 4:00 p.m. EDT and will conduct a conference call that will take place that day at 4:30 p.m. EDT.

Heron Therapeutics, Inc. announced today that it has entered into a securities purchase agreement to sell in a private placement to a group of new and existing institutional investors.